Ovarian Cancer: treatment map

Standard care plus compounds studied in the literature, organized by clinical readiness.

Educational only. This is not medical advice and not a recommendation. Confirm anything here with your oncology team.

Treatment map: Ovarian Cancer

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.

Interventions

Standard of care

Tested in people

Lab / animal

Named in lit.

Classes

Standard of care (0) Guideline option (16) Tested in people (22) Lab / animal only (11) Named in the literature (19)

Tested in people, by trial phase: Phase III ×2 · phase not reported ×20

Clinical evidence

Preclinical evidence

Standard of care

Guideline option

Tested in people

Lab / animal only

Named in the literature

Surgery & procedures

—

Radiotherapy

—

Chemotherapy

—

Targeted therapy

—

Immunotherapy

—

Hormonal therapy

—

Repurposed drugs

—

Supplements & natural agents

—

Other

—

Columns group into clinical evidence (used in, or tested on, people) and preclinical evidence (lab/animal, or only named in the literature). Cell = number of interventions; a dashed cell means none recorded there.

Established care — detail (16)

Chemotherapy

cisplatinFirst-line (advanced disease) FDA-approved for this cancer.	—	Guideline option
gemcitabine FDA-approved for this cancer.	—	Guideline option
carboplatinAdjuvant (after surgery) FDA-approved for this cancer.	—	Guideline option
cisplatin FDA-approved for this cancer.	—	Guideline option
carboplatin FDA-approved for this cancer.	—	Guideline option

Targeted therapy

bevacizumabMaintenance FDA-approved for this cancer.	—	Guideline option
bevacizumabAdjuvant (after surgery) FDA-approved for this cancer.	—	Guideline option
olaparibFirst-line (advanced disease) · BRCA-mut FDA-approved for this cancer.	—	Guideline option
rucaparibRecurrent or later-line · sBRCA/HRm FDA-approved for this cancer.	—	Guideline option
olaparibbiomarker-selected FDA-approved for this cancer.	—	Guideline option
rucaparibRecurrent or later-line FDA-approved for this cancer.	—	Guideline option
bevacizumab FDA-approved for this cancer.	—	Guideline option
rucaparib FDA-approved for this cancer.	—	Guideline option
olaparib FDA-approved for this cancer.	—	Guideline option
relacorilant FDA-approved for this cancer.	—	Guideline option
mirvetuximab soravtansine FDA-approved for this cancer.	—	Guideline option

Investigational & adjunct compounds — detail (52)

Phase III trial (2)

Meta-analysis (20)

Named in the literature

Lab / animal only

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.